Both Ends of the Spectrum: Talking Obesity Science with Samuel Klein, MD
As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of...
As an endocrine scientist and long-time Society member, I’m proud of the many programs our organization offers to both our basic and clinical researchers. The Endocrine Society, of course, represents professionals across the full range of our field, from bench to bedside. But I want to take this opportunity to highlight some of the work... As the onslaught of anti-obesity drugs hit the market in recent years, more research is being released about their potential side effects as well as their benefits. Endocrine News investigates two of these studies to gain more insight to how these “miracle drugs” could affect cardiac health. Two studies published in late 2025 examined cardiovascular...Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do
In the United States, American Heart Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular...New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk
Lilly’s Oral GLP-1 Orforglipron Demonstrates Superiority in Phase 3 Diabetes Trials
